Role of Cerebrolysin in cervical spondylotic myelopathy patients: a prospective randomized study.

Allam AFA, Abotakia TAA, Koptan W

The spine journal : official journal of the North American Spine Society14 Nov 2017Cited by 13 (Europe PMC)

PMID29155000DOI10.1016/j.spinee.2017.11.002PepBankPUB-29155000

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In cervical spondylotic myelopathy patients, improvement at 1 month occurred in 92% with Cerebrolysin versus 52% with placebo.
In plain wordsIn cervical myelopathy patients, improvement at 1 month occurred in 92% with Cerebrolysin versus 52% with placebo.
Peptide
Cerebrolysin
Outcome
IncreaseMyelopathy improvement at 1 month
Study
n = 192
Comparator
Placebo
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated · 4 weeksAs given in this study (human).
Measurements
Improvement
92%
Cerebrolysin at 1 month
Improvement
52%
placebo at 1 month
Source sentences
Summary
Myelopathy improved in 92% and 52% of patients at 1 month in Groups I and II, respectively; these changed at 6 months to 87% and 33%;
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 192 patients with cervical spondylotic myelopathy (CSM) were subdivided blindly into two equal groups.
Summary · context
Group I received Cerebrolysin and Group II received placebo for 4 weeks; both groups received celecoxib 200 mg for 4 weeks.
Report a problemFND-2915500001
02HumanRandomized controlled trialEfficacy outcome
In cervical spondylotic myelopathy patients, improvement at 6 months occurred in 87% with Cerebrolysin versus 33% with placebo.
In plain wordsIn cervical myelopathy patients, improvement at 6 months occurred in 87% with Cerebrolysin versus 33% with placebo.
Peptide
Cerebrolysin
Outcome
IncreaseMyelopathy improvement at 6 months
Study
n = 192
Comparator
Placebo
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated · 4 weeksAs given in this study (human).
Measurements
Improvement
87%
Cerebrolysin at 6 months
Improvement
33%
placebo at 6 months
Source sentences
Summary
Myelopathy improved in 92% and 52% of patients at 1 month in Groups I and II, respectively; these changed at 6 months to 87% and 33%;
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 192 patients with cervical spondylotic myelopathy (CSM) were subdivided blindly into two equal groups.
Summary · context
Group I received Cerebrolysin and Group II received placebo for 4 weeks; both groups received celecoxib 200 mg for 4 weeks.
Report a problemFND-2915500002
03HumanRandomized controlled trialEfficacy outcome
In cervical myelopathy patients, 13% with Cerebrolysin versus 60% with placebo neither improved nor deteriorated at 6 months.
In plain wordsIn cervical myelopathy patients, 13% with Cerebrolysin versus 60% with placebo neither improved nor deteriorated at 6 months.
Peptide
Cerebrolysin
Outcome
DecreaseNeither improvement nor deterioration at 6 months
Study
n = 192
Comparator
Placebo
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated · 4 weeksAs given in this study (human).
Measurements
Unchanged
13%
Cerebrolysin
Unchanged
60%
placebo
Source sentences
Summary
the remaining 13% in Group I neither improved nor deteriorated, whereas 60% in Group II neither improved nor deteriorated and 7% deteriorated
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 192 patients with cervical spondylotic myelopathy (CSM) were subdivided blindly into two equal groups.
Summary · context
Group I received Cerebrolysin and Group II received placebo for 4 weeks; both groups received celecoxib 200 mg for 4 weeks.
Report a problemFND-2915500003
04HumanRandomized controlled trialEfficacy outcome
In cervical myelopathy patients, mean JOA recovery rates differed significantly between Cerebrolysin and placebo at 1, 3, and 6 months.
In plain wordsIn cervical myelopathy patients, recovery scores differed significantly between Cerebrolysin and placebo at 1, 3, and 6 months.
Peptide
Cerebrolysin
Outcome
Direction not reportedJOA recovery rate
Study
n = 192
Comparator
Placebo
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated · 4 weeksAs given in this study (human).
Source sentences
Summary
with statistically significant differences when comparing the mean JOA recovery rate between the 2 groups at 1, 3, and 6 months.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 192 patients with cervical spondylotic myelopathy (CSM) were subdivided blindly into two equal groups.
Summary · context
Group I received Cerebrolysin and Group II received placebo for 4 weeks; both groups received celecoxib 200 mg for 4 weeks.
Report a problemFND-2915500004
05HumanRandomized controlled trialSafety outcome
In cervical myelopathy patients, Cerebrolysin patients improved or remained unchanged, whereas 7% of placebo patients deteriorated.
In plain wordsIn cervical myelopathy patients, Cerebrolysin patients improved or remained unchanged, whereas 7% of placebo patients deteriorated.
Peptide
Cerebrolysin
Outcome
DecreaseNeurologic deterioration
Study
n = 192
Comparator
Placebo
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated · 4 weeksAs given in this study (human).
Measurements
Neurologic deterioration proportion
7%
Group II (placebo), 6 months
Source sentences
Summary
these changed at 6 months to 87% and 33%; the remaining 13% in Group I neither improved nor deteriorated, whereas 60% in Group II neither improved nor deteriorated and 7% deteriorated
Summary
Cerebrolysin over 4 weeks is safe and effective for the improvement of CSM as compared with placebo, with no reported cases of neurologic deterioration over 6 months of follow-up.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 192 patients with cervical spondylotic myelopathy (CSM) were subdivided blindly into two equal groups.
Summary · context
Group I received Cerebrolysin and Group II received placebo for 4 weeks; both groups received celecoxib 200 mg for 4 weeks.
Report a problemFND-2915500005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.